by radioimmunoassay (R1A) has proved difficult for two reasons.6 First, highly avid antisera are rare and therefore either expensive or not generally available (1,2). Second, the concentrations of ACTh in the circulation in healthy subjects are low. These problems can be overcome to a certain extent by increasing the concentration of ACTH by using an extraction procedure before the assay (3-5) and by increasing the incubation times (5, 6), but these maneuvers make the assay technically more demanding, imprecise, and slow. Two-site or "sandwich"-type immunoradiometric assays (mMAs) offer theoretical advantages of sensitivity, precision, and incubation time over competitive immunoassays. Time-resolved fluoroimmunoassay has been used to determine peptides and steroids (11, 12). The two-site immunofluorometric assays (irMA) with a fluorescent chelate of europium offer an alternative non-isotopic immunoassay with high sensitivity. Highly sensitive was based on europium-labeled antibodies have been described for alphafetoprotein (13), thyrotropin, lutropin(11), and choriogonadotropin (14).
immunoactive ACTh in certain pathological situations. That assay also offers better sensitivity than RIAs involving the same individual antibodies (9, 10) and has all the advantages associated with use of monoclonal antibodies. However, the use of iodinated monoclonal antibody is encumbered with the recognized hazards of radioactivity and the need to prepare the radiolabeled antibody approximately every eight weeks. This has led to the search for non-isotopic alternatives.
Time-resolved fluoroimmunoassay has been used to determine peptides and steroids (11, 12) . The two-site immunofluorometric assays (irMA) with a fluorescent chelate of europium offer an alternative non-isotopic immunoassay with high sensitivity. Highly sensitive was based on europium-labeled antibodies have been described for alphafetoprotein (13), thyrotropin, lutropin (11) , and choriogonadotropin (14).
Here we report the development of a sensitive IFMA for measurement of ACTH in plasma. We use the same monoclonal antibodies as described in the mr (8), and we evaluate the performance of the IFMA in comparison with that of the IRMA.
Materials and Methods

Monoclonal Antibodies
Two monoclonal antibodies-lA 12, specific for the mid Nterminal region of ACT!-! (Acm 10-18), and 2A3, specific for the C-terminal region (ACTH 23-39)-were purified as described previously (10).
Other Materials
Purified human ACT!-! 1-39, other peptides, normal sheep serum, and horse serum were obtained as described elsewhere (8). All peptides were prepared and stored as described by Lambert et al. (15) . The enhancement solution (16) was purchased from LKB-Wallac, S. Croydon, U.K. The microtiter-well strips were from Systems U.K. Ltd., Uxbridge, U.K. Dexamethasone-suppressed plasma was collected from apparently healthy volunteers (ages 19-39 years) 8 h after administration of 1.5 mg of dexamethasone at 23:00 h.
Instrumentation
The microtiter-well plates were shaken on a Dynatech Microtiter shaker, and the europium fluorescence was measured with a 1230 Arcus time-resolved fluorometer (LKBWallac), with an automatic sample changer and a measuring time of 1 s per sample (1).
For the IRMA,
samples were counted in a multi-well gamma counter (Model 1260; LKB-Wallac).
IRMA Assay
Each of the antibodies was coupled to Sephacryl S300 (Pharmacia, Milton Keynes, U.K.) according to the method of Wright and Hunter (18) or iodinated by the Chioramine T method (10) . The assay procedure is outlined below in Table  1 ; details of the optimized assay are described elsewhere (8). 
Concentration of europium-labeled antibody:
We tested labeled 1A12 and 2A3 antibodies in a simultaneous addition assay (one 4-h incubation) at three (1:250, 1:500, 1:1000) and four (1:100, 1:250, 1:500, 1:1000) dilutions, respectively. The washing steps and the use of enhancement solution were as described above.
incubation protocols: We tested several incubation times for simultaneous and sequential addition of the ACTH 1-39 and labeled antibody.
Standard matrix: Using the optimized sequential addition protocol, we compared results for ACTH 1-39 standards diluted in assay buffer alone and diluted in assay buffer mixed with dexamethasone-suppressed plasma (500 to 1000 mL per liter of assay buffer), human serum (100 to 1000 mL/L), or horse serum (100 to 1000 mLIL).
Optimized assay protocol: To microtiter wells coated with antibody 2A3 (30 mgfL) we added 200 L of purified human cm 1-39 standards (diluted in assay diluent containing 100 mL of horse serum per liter: buffer A), and incubated for 4 h at 4 #{176}C, then washed the plates three times. We then added 200 L of labeled antibody 1A12 (7.8 europium ions per molecule of IgG, and diluted 1000-fold in buffer A containing 0.5 mL of normal sheep serum per liter) and incubated for 1 h at 4 #{176}C. The plates were washed and enhancement solution added as described previously. The method is summarized in Table 1 .
Assay Evaluation
IRMA
and IFMA comparison: We calculated the assay detection limit from the 99% confidence interval of results for the zero ACTH 1-39 standard. The mean within-assay precision of the IRMA was calculated by using the computer package of Raab and McKenzie (19) to evaluate results of four assays with a total of 211 patients' samples. The mean within-assay precision of the IFMA was calculated from the spline curve-fit package supplied with the fluorometer (four assays with a total of 164 patients' samples) Specificity: The specificities and 1C50 values (concentration of peptide that causes 50% displacement of radioligand from antibody) for antibodies 2A3 and 1A12 are described elsewhere (9) . The specificity of the irMA was determined by examining the cross reactivity of ACTH 1-24 and 18-39, amelanotropin, nonamidated a-melanotropin, and fractions obtained from the Sephadex G75 purification of an ACTHsecreting pituitary tumor. The fractions with approximate molecular masses of 22, 31, and 34 kDa are considered to correspond to pro-y-melanotropin-Acm (22 kDa), proopiomelanocortin (31 kDa), and preproopiomelanocortin (34 kDa) (20). These fractions were dissolved in 1 mL of 10 mmolJL HC1 and diluted10-fold in buffer A.
interference from fragments: The individual antibodies will bind to a-melanotropin, ACTII 18-39, and ACT!-! 1-24 in an RIA. If any of these fragments occur in significant quantities in patients' samples, they may interfere with the binding of the two antibodies to ACTH in the LFMA. Therefore, we added 100 tL of a-melanotropin, a-melanotropmn free acid, ACTH 18-39, and ACTH 1-24 at concentrations as great as 10 000 ngIL to 100 jiL of ACTH 1-39 standards (100 or 1000 ngIL) and compared the results with those for ACTH 1-39 alone (100 L of standard + 100 L of buffer A). We assayed heparmnized plasma collected from 17 normal volunteers and from 10 metyrapone-stimulated normal subjects, samples left over from insulin hypoglycemia tests of patients without evidence of hypothalamic-pituitary-adrenal dysfunction, and selected patients' samples as described elsewhere (8). All samples were stored at -70 #{176}C before assay by IRMA and IFMA. Table 2 shows the sensitivity and signal-to-background ratios (counts/mm for each Ac'ru concentration over counts/ mm for zero ACT!-! concentration) achieved with europiumlabeled antibodies at different specific activities and dilutions. Increasing the specific activity of the label for either antibody did not improve the assay sensitivity. For labeled antibody 1A12 the 1000-fold dilution produced the most sensitive assay, with the highest signal-to-background ratio. In contrast, with labeled antibody 2A3 the most sensitive assay was obtained at the lower dilution, but assays with this antibody were all relatively insensitive, with low signal-to-background ratios across the standard curve, We therefore used in the optimized assay 1000-fold diluted europium-labeled antibody 1A12, at 7.8 europium ions per IgG molecule. For antibody 2A3 used in concentrations of 7-50 mg/L, the standard curves were superimposable. In the optimized assay we used a 30 mgIL concentration to coat the microtiter wells. Table 3 shows the effect of varying the number and duration of the incubation periods. None of the assay protocols involving labeled antibody 2A3 produced an acceptable sensitivity. With labeled antibody 1A12 the simultaneous 4-h and the sequential 4 + 1-h assays were the most sensitive, yielding high signal-to-background ratios. We chose the 4 + 1-h protocol as the optimized assay. Prolonging the second incubation period (after the addition of labeled antibody) progressively decreased the assay sensitivity and the signal-to-background ratios. Because assay results for dilutions of ACTH 1-39 standards in assay diluent, dexamethasone-suppressed plasma, human serum, or horse serum are virtually superimposable, 
Results
IFMA Optimization
Comparison of IRMA and IFMA
The optimized assay methods compared in this study are shown in Table 1 . At all stages (reagent addition, incubation, separation, and counting) the IRMA is considerably more time-consuming than the IRMA.
The minimum detection limits of the IFMA and IRMA, as defined by the minimum ACTH dose that can be reliably (99% confidence interval) distinguished from zero, are 4.0 (SD 1.0) ng/L and 3.5 (SD 0.8) ng/L, respectively, as calculated from seven assays. From the mean within-assay precision profiles, we determined the working ranges, as defined by a CV of <10%, to be 25 to >1000 ng/L for the IFMA and 22 to >1000 ngfL for the IRMA (Figure 2) . The within-assay precision from samples measured in both assays and the between-assay precision for assays of further samples are shown in Table 4 . The precisions (CVs) calculated are similar for both assays, but that for the IFMA never falls below 8% over the range of the standard curve whereas that for the IRMA reaches <2% (Figure 2) . The analytical recovery of ACTH added to dexamethasone-suppressed plasma is also comparable for both assays ( 
xNumbers in parenthesesare the number of assays or replicatesof dexamethasone-suppressedhuman plasmato which purified humanACTH has been added. (5) 94 (7) re the number of assays.
105 (6) 136 (6) 108 (6) 100 (6) dexamethasone-suppressed plasma and 100% for the patients' samples.
Normal Ranges
The mean ACTH concentrations (and ranges) measured in normal volunteers by IFMA 
Discussion
The irMA we describe represents a marked technical improvement in terms of simplicity and speed, factors that have severely limited ACTH immunoassays in the past. The assay is sensitive, precise, free from matrix effects, detects precursor peptides of diagnostic importance, and gives results that correlate well with those of a fully evaluated IRMA
of ACTH (8).
The assay can be completed in one day, with use of a 4-h simultaneous or a 4 + 1-h sequential addition protocol; no improvement of assay sensitivity or precision was gained from increasing or decreasing these times. The principal factor controlling the assay detection limit is the avidity of the labeled antibody, but the background fluorescence and its variation, and the specific activity of the labeled antibody, also contribute. Compared with limited reagent assays (e.g., RIAs) the immunometric assay enhances potential sensitivity (21) and both the IFMA we describe and the IRMA show better sensitivity than does the RIA with the same antibodies (10) . Similarly, labeling the more avid antibody produces the most sensitive assays (21), whether in the IRMA (10) or the waa with labeled antibody 1A12. The specific activity of the europium label is about 106 times that of rn1 (17) , and improved sensitivity has been related to increased specific activity in an immunochemiluminometric assay (23). However, sensitivity is only marginally improved with higher-specific-activity labels in the IF!s&A of ACTH. Whether this is the result of relatively poor precision at low ACT!! concentrations or is simply related to the antibody itself is not yet known.
Analytical recovery of ACTH added to dexamethasonesuppressed plasma is excellent as measured in the irMA; and, because dilution curves for endogenous ACT!-! parallel that for authentic ACT!!, we conclude that the assay accurately measures ACTH in unextracted human plasma.
The IFMA results of patients' samples are consistent with previous best estimates by immunoassay, and there is excellent correlation between results by the IRMA and IFMA over the wide range tested.
The assay is specific for ACTH 1-39, itsprecursorproopiomelanocortin, and the 22-kDa form of ACTH, and it does not detect fragments.
For diagnostic purposes this specificity is advantageous, because the 22-kDa peptide is a major circulating component of total ACTH immunoactivity in patients with the ectopic ACT!! syndrome and is also present to a lesser extent in normal subjects and patients with aggressive pituitary tumors (20).
A major advantage of the IFMA is the stability of the europium-labeled antibody, which we have found to be stable for 50 weeks with no reduction in sensitivity, precision, or signal-to-background ratios, whereas the '251-labeled antibody 1A12 has a shelf life of only eight weeks. Consequently, coating the microtiter-well plates is the only routine reagent production required for the w. This procedure is technically easy and is carried out in our laboratory monthly.
In conclusion, the IRMA has all the advantages of two-site excess reagent assays plus the additional benefits of speed, technical simplicity, and label stability. It thus provides an attractive alternative for the nonradioactive measurement of ACTH.
